Sertaconazole
- Atc Codes:D01AC14
- CAS Codes:99592-32-2
- PHARMGKB ID:99592-32-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Monazol; Germany: Mykosert, Zalain; Greece: Fuganol; Hungary: Zalain; Italy: Sertacream, Sertaderm, Sertadie, Sertagyn; Portugal: Dermofix, Sertopic; Spain: Dermofix, Dermoseptic, Ginedermofix, Zalain.
North America
USA: Ertaczo.
Latin America
Brazil: Zalain; Mexico: Ertaczo.
Drug combinations
Chemistry
Sertaconazole: C~20~H~15~Cl~3~N~2~OS. Mw: 437.77. (±)-1-[2,4-Dichloro-β-[(7-chlorobenzo[b]thien-3-yl)methoxy]phenethyl]imidazole. CAS-99592-32-2.
Pharmacologic Category
Antifungals; Azoles. Topical Antifungal Agent. (ATC-Code: D01AC14).
Mechanism of action
Imidazole-derivative azole antifungal. Usually fungistatic. May be fungicidal at high concentrations. Presumably exerts its antifungal activity by altering cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition. Fungistatic activity may result from interference with ergosterol synthesis. Fungicidal activity at high concentrations may result from direct physiochemical effect on fungal cell membrane. Spectrum of antifungal activity includes many fungi, including dermatophytes and yeasts. Also has in vitro activity against some Gram-positive bacteria. Active in vitro against dermatophytes such as Epidermophyton floccosum, Microsporum audouini, M. canis, M. gypseum, M. racemosum, Trichophyton erinacei, T. interdigitale, T. mentagrophytes, T. rubrum, T. schoenleinii, T. soudanese, T. terreste, T. tonsurans, T. verrucosum, and T. violaceum. Also active in vitro against Malassezia furfur (Pityrosporum orbiculare or P. ovale). Active in vitro against candida such as C. albicans, C. beigelii, C. dubliniensis, C. famata, C. glabrata (formerly Torulopsis glabrata), C. guilliermondii, C. holmii, C. humicola, C. inconspicua, C. intermedia, C. krusei, C. lambica, C. lipolytica, C. lusitaniae, C. parapsilosis, C. pulcherrima, C. pseudotropicalis, C. rugosa, and C. tropicalis. In vitro resistance to sertaconazole described in some isolates of T. mentagrophytes, T. rubrum, and M. canis, and C. albicans serotype B vaginal.
Therapeutic use
Tinea pedis (athlete’s foot). Vulvovaginal candidiasis.
Pregnancy and lactiation implications
There are no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to sertaconazole, other imidazoles, or any component of the formulation.
Warnings and precautions
Discontinue drug if sensitivity or irritation occurs. Avoid contact with eyes.
Vaginal use: Administration is preferred at bedtime, in order to encourage local action and vaginal absorption.